[
  {
    "ts": null,
    "headline": "Repay Taps Conduent Executive Houser for CFO Role",
    "summary": "Repay Taps Conduent Executive Houser for CFO Role",
    "url": "https://finnhub.io/api/news?id=b63dcbde4b1afd6a2916d99d09fa1224fa902cb54966166a8e88ade6110e8551",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754933460,
      "headline": "Repay Taps Conduent Executive Houser for CFO Role",
      "id": 136331959,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Repay Taps Conduent Executive Houser for CFO Role",
      "url": "https://finnhub.io/api/news?id=b63dcbde4b1afd6a2916d99d09fa1224fa902cb54966166a8e88ade6110e8551"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)",
    "summary": "Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=33e219893e5ff70d5426b444ee5aa22e2dd7a6608d34f9b1f1e8f72f4863156f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754930844,
      "headline": "Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)",
      "id": 136311902,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372801568/image_1372801568.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider confidence, click for why VRTX stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=33e219893e5ff70d5426b444ee5aa22e2dd7a6608d34f9b1f1e8f72f4863156f"
    }
  },
  {
    "ts": null,
    "headline": "The Galien Foundation Announces 2025 Prix Galien USA Nominees for \"Best Biotechnology Product,\" \"Best Pharmaceutical Product\" and \"Best Product for Rare/Orphan Diseases\"",
    "summary": "The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2025 Prix Galien USA Award nominees for \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Disease.\" Winners will be announced during the Prix Galien USA Awards Ceremony on October 30, 2025, at the American Museum of Natural History in New York City.",
    "url": "https://finnhub.io/api/news?id=cb2d62130001855638022be09717ceb1289ea6c6e673bb335741006702f9102d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754928000,
      "headline": "The Galien Foundation Announces 2025 Prix Galien USA Nominees for \"Best Biotechnology Product,\" \"Best Pharmaceutical Product\" and \"Best Product for Rare/Orphan Diseases\"",
      "id": 136310598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2025 Prix Galien USA Award nominees for \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Disease.\" Winners will be announced during the Prix Galien USA Awards Ceremony on October 30, 2025, at the American Museum of Natural History in New York City.",
      "url": "https://finnhub.io/api/news?id=cb2d62130001855638022be09717ceb1289ea6c6e673bb335741006702f9102d"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?",
    "summary": "MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.",
    "url": "https://finnhub.io/api/news?id=d442286596621996ceafd5dc69f37ccb03f38b5bdff8a45c6c1d96394132cfec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754926320,
      "headline": "Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?",
      "id": 136310504,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.",
      "url": "https://finnhub.io/api/news?id=d442286596621996ceafd5dc69f37ccb03f38b5bdff8a45c6c1d96394132cfec"
    }
  },
  {
    "ts": null,
    "headline": "IO Biotech Slides After Cancer-Vaccine Study Misses Primary Endpoint",
    "summary": "IO Biotech Slides After Cancer-Vaccine Study Misses Primary Endpoint",
    "url": "https://finnhub.io/api/news?id=5a3856851970588b68ae64a47afc28cfab3ebc302c64d2cb06103befaac10249",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754925180,
      "headline": "IO Biotech Slides After Cancer-Vaccine Study Misses Primary Endpoint",
      "id": 136331960,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "IO Biotech Slides After Cancer-Vaccine Study Misses Primary Endpoint",
      "url": "https://finnhub.io/api/news?id=5a3856851970588b68ae64a47afc28cfab3ebc302c64d2cb06103befaac10249"
    }
  },
  {
    "ts": null,
    "headline": "Merck Stock Down 4% Since Q2 Results: How to Play the Stock",
    "summary": "Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.",
    "url": "https://finnhub.io/api/news?id=e14dd5f232a31b020fd8d9e51ea1ca24eb932a3a1ecf88a2e97d5224fe95c7f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754918220,
      "headline": "Merck Stock Down 4% Since Q2 Results: How to Play the Stock",
      "id": 136310600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.",
      "url": "https://finnhub.io/api/news?id=e14dd5f232a31b020fd8d9e51ea1ca24eb932a3a1ecf88a2e97d5224fe95c7f9"
    }
  },
  {
    "ts": null,
    "headline": "IO Biotech sees path forward for skin cancer vaccine despite study setback",
    "summary": "A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe it still could win U.S. approval.",
    "url": "https://finnhub.io/api/news?id=0f404894a61b0a9cd3f3109e3d809b9d66d9201194adee39776076468ee1e613",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754913720,
      "headline": "IO Biotech sees path forward for skin cancer vaccine despite study setback",
      "id": 136310602,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe it still could win U.S. approval.",
      "url": "https://finnhub.io/api/news?id=0f404894a61b0a9cd3f3109e3d809b9d66d9201194adee39776076468ee1e613"
    }
  },
  {
    "ts": null,
    "headline": "IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed",
    "summary": "Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study’s statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-",
    "url": "https://finnhub.io/api/news?id=ec813dd9db1347c4dd952d741fde8ffef544f2013e65a88f51adf7f6476a3a03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754913600,
      "headline": "IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed",
      "id": 136294331,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study’s statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-",
      "url": "https://finnhub.io/api/news?id=ec813dd9db1347c4dd952d741fde8ffef544f2013e65a88f51adf7f6476a3a03"
    }
  },
  {
    "ts": null,
    "headline": "Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities",
    "summary": "Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in top-tier pharmaceutical stocks due to strong fundamentals and future AI benefits. Read more here",
    "url": "https://finnhub.io/api/news?id=256ea8bb2e23b7ca971a343047437044e07eec4a066f579cd2fa3dc2bb15f49b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754907483,
      "headline": "Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities",
      "id": 136294096,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in top-tier pharmaceutical stocks due to strong fundamentals and future AI benefits. Read more here",
      "url": "https://finnhub.io/api/news?id=256ea8bb2e23b7ca971a343047437044e07eec4a066f579cd2fa3dc2bb15f49b"
    }
  },
  {
    "ts": null,
    "headline": "Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations",
    "summary": "The Non-metastatic Prostate Cancer market is witnessing substantial growth driven by increasing demand for targeted therapies and innovative treatment options. Non-metastatic prostate cancer, confined to the prostate gland, benefits from early detection methods like PSA testing and multiparametric MRI, facilitating timely intervention. Key players like Johnson & Johnson, Astellas Pharma, and Pfizer are pioneering advancements with androgen receptor inhibitors and precision medicine. Despite sign",
    "url": "https://finnhub.io/api/news?id=7ed66726fb860b103f275cf311c614095bcaca667705b72b586e98df5fdd96f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754903580,
      "headline": "Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations",
      "id": 136292298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Non-metastatic Prostate Cancer market is witnessing substantial growth driven by increasing demand for targeted therapies and innovative treatment options. Non-metastatic prostate cancer, confined to the prostate gland, benefits from early detection methods like PSA testing and multiparametric MRI, facilitating timely intervention. Key players like Johnson & Johnson, Astellas Pharma, and Pfizer are pioneering advancements with androgen receptor inhibitors and precision medicine. Despite sign",
      "url": "https://finnhub.io/api/news?id=7ed66726fb860b103f275cf311c614095bcaca667705b72b586e98df5fdd96f9"
    }
  }
]